Literature DB >> 26593077

Evidence-Based Pharmacologic Therapies for Prevention of Bronchopulmonary Dysplasia: Application of the Grading of Recommendations Assessment, Development, and Evaluation Methodology.

Erik A Jensen1, Elizabeth E Foglia1, Barbara Schmidt2.   

Abstract

Bronchopulmonary dysplasia (BPD) is the most common chronic complication of extreme preterm birth. The authors applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to pharmacologic therapies found to prevent BPD. Caffeine and vitamin A are the only medications shown in high-quality studies to prevent BPD without the risk of clinically important adverse effects. Dexamethasone is effective for the prevention of BPD; but for many infants, the increased risks of hypertrophic cardiomyopathy, gastrointestinal perforation, and cerebral palsy outweigh this benefit. Several medications are currently under investigation for the prevention of BPD, but few are novel agents.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Azithromycin; Bronchopulmonary dysplasia; Caffeine; Chronic lung disease; Dexamethasone; Vitamin A

Mesh:

Substances:

Year:  2015        PMID: 26593077     DOI: 10.1016/j.clp.2015.08.005

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  11 in total

Review 1.  Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review.

Authors:  Ann A Simones; Daniel J Beisang; Angela Panoskaltsis-Mortari; Kari D Roberts
Journal:  Pediatr Res       Date:  2017-10-25       Impact factor: 3.756

Review 2.  Nutritional Supplements to Improve Outcomes in Preterm Neonates.

Authors:  Mohan Pammi; Ravi M Patel
Journal:  Clin Perinatol       Date:  2022-04-21       Impact factor: 2.642

Review 3.  Should we still use vitamin A to prevent bronchopulmonary dysplasia?

Authors:  X I Couroucli; J L Placencia; L A Cates; G K Suresh
Journal:  J Perinatol       Date:  2016-05-26       Impact factor: 2.521

Review 4.  Preventing Continuous Positive Airway Pressure Failure: Evidence-Based and Physiologically Sound Practices from Delivery Room to the Neonatal Intensive Care Unit.

Authors:  Clyde J Wright; Laurie G Sherlock; Rakesh Sahni; Richard A Polin
Journal:  Clin Perinatol       Date:  2018-02-28       Impact factor: 3.430

5.  Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.

Authors:  Matthew A Rysavy; Lei Li; Jon E Tyson; Erik A Jensen; Abhik Das; Namasivayam Ambalavanan; Matthew M Laughon; Rachel G Greenberg; Ravi M Patel; Claudia Pedroza; Edward F Bell
Journal:  J Pediatr       Date:  2021-05-15       Impact factor: 6.314

6.  Developmentally Regulated Innate Immune NFκB Signaling Mediates IL-1α Expression in the Perinatal Murine Lung.

Authors:  Brittany Butler; Robyn De Dios; Leanna Nguyen; Sarah McKenna; Sankar Ghosh; Clyde J Wright
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

7.  Hospitalization costs associated with bronchopulmonary dysplasia in the first year of life.

Authors:  Wannasiri Lapcharoensap; Mihoko V Bennett; Xiao Xu; Henry C Lee; Dmitry Dukhovny
Journal:  J Perinatol       Date:  2019-11-07       Impact factor: 2.521

Review 8.  Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant.

Authors:  Lidys Rivera; Roopa Siddaiah; Christiana Oji-Mmuo; Gabriela R Silveyra; Patricia Silveyra
Journal:  Front Pediatr       Date:  2016-03-31       Impact factor: 3.418

Review 9.  Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants.

Authors:  E E Foglia; E A Jensen; H Kirpalani
Journal:  J Perinatol       Date:  2017-06-01       Impact factor: 2.521

10.  Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis.

Authors:  Xiao-Bei Si; Xu-Min Zhang; Shuai Wang; Yu Lan; Shuo Zhang; Lin-Yu Huo
Journal:  World J Gastroenterol       Date:  2019-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.